706 results on '"Kapiteijn E"'
Search Results
2. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol
3. Correction to: Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases
4. Health-state utilities in long-term advanced melanoma survivors comparable with the general population
5. Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma
6. Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry
7. A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
8. Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial
9. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
10. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
11. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
12. Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study
13. Seasonal variation of anti-PD-1 outcome in melanoma—Results from a Dutch patient cohort
14. Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort
15. A prediction model for response to immune checkpoint inhibition in advanced melanoma
16. Treatment strategies and overall survival for incurable metastatic colorectal cancer – A EURECCA international comparison including 21,196 patients from the Netherlands and Norway
17. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
18. A unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literature
19. Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort
20. Endocriene tumoren
21. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
22. Adjuvant treatment with anti-PD-1 in acral melanoma: a nationwide study
23. Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort.
24. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
25. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.
26. Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry.
27. Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.
28. A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.
29. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma
30. Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
31. Health-state utilities in long-term advanced melanoma survivors comparable with the general population
32. CT radiomics to predict checkpoint inhibitors treatment outcomes in patients with advanced cutaneous melanoma
33. 31P The IOpener study: Tyrosine kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer
34. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
35. 849P Time from primary melanoma to first distant recurrence in relation to survival outcomes in metastatic melanoma
36. 791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma
37. 859P The influence of hematologic malignancies on response to immune checkpoint inhibition in patients with advanced melanoma
38. 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)
39. 812P Early experiences in adjuvant treatment of melanoma: Real-world data on tolerability, safety and efficacy
40. 860P The IOpener study: Tyrosine kinase activity in peripheral lymphocytes to predict durable response to immune checkpoint inhibition in patients with advanced melanoma
41. 115P Gene rearrangements, actionability and access to precision medicine: Results from the ARCAGEN study
42. LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial
43. 1140TiP Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
44. 6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
45. Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer
46. Survival of stage IV melanoma in Belgium and the Netherlands
47. Health-Related Quality of Life in Adrenocortical Carcinoma: Development of the Disease-Specific Questionnaire ACC-QOL and Results from the PROFILES Registry
48. The unfavorable effects of COVID-19 on Dutch advanced melanoma care
49. Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice
50. Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.